PT889880E - Di-hidrato de eprosartano e um processo para a sua producao e formulacao - Google Patents

Di-hidrato de eprosartano e um processo para a sua producao e formulacao

Info

Publication number
PT889880E
PT889880E PT97917004T PT97917004T PT889880E PT 889880 E PT889880 E PT 889880E PT 97917004 T PT97917004 T PT 97917004T PT 97917004 T PT97917004 T PT 97917004T PT 889880 E PT889880 E PT 889880E
Authority
PT
Portugal
Prior art keywords
eprosartan
hydrate
formulation
production
Prior art date
Application number
PT97917004T
Other languages
English (en)
Inventor
Nageswara R Palepu
Gopadi M Venkatesh
Sarma Duddu
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21765344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT889880(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PT889880E publication Critical patent/PT889880E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/556Angiotensin converting enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT97917004T 1996-03-29 1997-03-26 Di-hidrato de eprosartano e um processo para a sua producao e formulacao PT889880E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1441496P 1996-03-29 1996-03-29

Publications (1)

Publication Number Publication Date
PT889880E true PT889880E (pt) 2003-09-30

Family

ID=21765344

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97917004T PT889880E (pt) 1996-03-29 1997-03-26 Di-hidrato de eprosartano e um processo para a sua producao e formulacao

Country Status (36)

Country Link
EP (1) EP0889880B1 (pt)
JP (1) JP4316013B2 (pt)
CN (2) CN1214682A (pt)
AP (1) AP901A (pt)
AR (1) AR006439A1 (pt)
AT (1) ATE239723T1 (pt)
AU (1) AU726694B2 (pt)
BG (1) BG64095B1 (pt)
BR (1) BR9708336A (pt)
CA (1) CA2250395C (pt)
CZ (1) CZ293345B6 (pt)
DE (1) DE69721749T2 (pt)
DK (1) DK0889880T3 (pt)
DZ (1) DZ2199A1 (pt)
EA (1) EA001958B1 (pt)
EG (1) EG23889A (pt)
ES (1) ES2198564T3 (pt)
HK (1) HK1016594A1 (pt)
HU (1) HU228263B1 (pt)
ID (1) ID16507A (pt)
IL (1) IL126319A0 (pt)
MA (1) MA24437A1 (pt)
MY (1) MY117682A (pt)
NO (2) NO311760B1 (pt)
NZ (1) NZ332008A (pt)
OA (1) OA11176A (pt)
PL (1) PL188816B1 (pt)
PT (1) PT889880E (pt)
RO (1) RO118870B1 (pt)
SK (1) SK282346B6 (pt)
TR (1) TR199801954T2 (pt)
TW (1) TW434239B (pt)
UA (1) UA49880C2 (pt)
UY (1) UY24504A1 (pt)
WO (1) WO1997036874A1 (pt)
ZA (1) ZA972686B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999000383A1 (en) * 1997-06-27 1999-01-07 Smithkline Beecham Corporation Eprosartan monohydrate
NZ504565A (en) * 1997-11-17 2002-11-26 Smithkline Beecham Corp High drug load immediate and modified release oral dosage formulations of eprosartan used to block angiotensin II (AII) receptors in the treatment of hypertension, congestive heart failure and renal failure
US6558699B2 (en) * 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
PL342684A1 (en) 1998-03-04 2001-07-02 Takeda Chemical Industries Ltd Preperation featured by reterded release of aii antagonist, production and application of such preparation
ZA991922B (en) * 1998-03-11 1999-09-13 Smithkline Beecham Corp Novel compositions of eprosartan.
CA2338256C (en) * 1998-07-20 2008-09-23 Smithkline Beecham Corporation Bioenhanced formulations comprising eprosartan in oral solid dosage form
GB9820405D0 (en) * 1998-09-18 1998-11-11 Smithkline Beecham Plc Process
AU1157500A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Medicaments based on combinations of lacidipine and telmisartan or of physiological derivatives thereof
AU1042199A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Antihypertensive medicaments containing lacidipine and telmisartan
ATE289204T1 (de) * 1999-04-28 2005-03-15 Takeda Pharmaceutical Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie
GB9920919D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel compound
GB9920917D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel process
PL365696A1 (en) * 2000-04-12 2005-01-10 Novartis Ag Combination of organic compounds
AU2002364381A1 (en) * 2001-11-23 2003-06-10 Solvay Pharmaceuticals Gmbh Hypertonia treatment during the acute phase of a cerebrovascular accident
KR100517638B1 (ko) 2002-04-08 2005-09-28 주식회사 엘지생명과학 게미플록사신 산염의 새로운 제조방법
RU2004137109A (ru) * 2002-05-17 2005-10-10 Новартис АГ (CH) Комбинация блокатора рецептора ангиотензина ii и бетаблокатора для вторичной профилактики инфаркта миокарда
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
AU2004208615C1 (en) 2003-01-31 2010-05-13 Daiichi Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
US8361507B2 (en) 2007-07-25 2013-01-29 Hetero Drugs Limited Eprosartan mesylate crystalline particles and a process for preparing pure eprosartan
WO2009084028A2 (en) * 2007-12-03 2009-07-09 Neuland Laboratories Ltd Improved process for manufacturing anhydrous (e)-3-[2-butyl-1- {(4-carboxyphenyl) methyl}-1h-imidazole-5-yl]-(thiophen-2- ylmethyl)prop-2-enoic acid methane sulfonate
CN101333216A (zh) * 2008-08-03 2008-12-31 浙江华海药业股份有限公司 一种新的依普罗沙坦甲磺酸盐成盐工艺
CN113354553B (zh) * 2021-06-03 2023-09-15 北京宝诺康医药科技有限公司 一种甲氧氯普胺单盐酸盐一水合物的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
US5312828A (en) * 1989-06-14 1994-05-17 Finkelstein Joseph A Substituted imidazoles having angiotensin II receptor blocking activity
WO1992010189A1 (en) * 1990-12-14 1992-06-25 Smithkline Beecham Corporation Imidazolyl-alkenoic acids

Also Published As

Publication number Publication date
EP0889880B1 (en) 2003-05-07
AP9700956A0 (en) 1997-04-30
UY24504A1 (es) 1997-09-19
HU228263B1 (en) 2013-02-28
PL329046A1 (en) 1999-03-01
HK1016594A1 (en) 1999-11-05
BG102822A (en) 1999-11-30
CA2250395A1 (en) 1997-10-09
NO984503D0 (no) 1998-09-28
NO2002005I1 (no) 2002-09-02
CN1332167A (zh) 2002-01-23
SK132298A3 (en) 1999-03-12
AU726694B2 (en) 2000-11-16
DE69721749D1 (de) 2003-06-12
BG64095B1 (bg) 2003-12-31
IL126319A0 (en) 1999-05-09
WO1997036874A1 (en) 1997-10-09
HUP9902769A2 (hu) 2000-03-28
PL188816B1 (pl) 2005-04-29
CA2250395C (en) 2005-09-06
NO311760B1 (no) 2002-01-21
HUP9902769A3 (en) 2000-04-28
UA49880C2 (uk) 2002-10-15
TW434239B (en) 2001-05-16
AP901A (en) 2000-11-23
NZ332008A (en) 1999-05-28
BR9708336A (pt) 1999-08-03
AR006439A1 (es) 1999-08-25
MY117682A (en) 2004-07-31
JP4316013B2 (ja) 2009-08-19
TR199801954T2 (xx) 1998-12-21
MA24437A1 (fr) 1998-10-01
OA11176A (en) 2003-05-13
DE69721749T2 (de) 2004-03-25
CN1214682A (zh) 1999-04-21
JP2000508632A (ja) 2000-07-11
EA199800873A1 (ru) 1999-02-25
EA001958B1 (ru) 2001-10-22
ID16507A (id) 1997-10-02
AU2547097A (en) 1997-10-22
NO984503L (no) 1998-09-28
CZ293345B6 (cs) 2004-04-14
RO118870B1 (ro) 2003-12-30
SK282346B6 (sk) 2002-01-07
EG23889A (en) 2007-12-12
EP0889880A4 (en) 1999-06-23
DZ2199A1 (fr) 2002-12-03
DK0889880T3 (da) 2003-09-01
EP0889880A1 (en) 1999-01-13
ZA972686B (en) 1997-09-29
CZ310198A3 (cs) 1999-03-17
ES2198564T3 (es) 2004-02-01
ATE239723T1 (de) 2003-05-15

Similar Documents

Publication Publication Date Title
PT889880E (pt) Di-hidrato de eprosartano e um processo para a sua producao e formulacao
PT909327E (pt) Eritromicinas e processo para a sua preparacao
BR9503638A (pt) Composto processo para sua produção e formulação farmacêutica
PT799866E (pt) Negro-de-fumo e processo para a sua preparacao
PT876444E (pt) Composicoes solventes parafinicas de elevada pureza e processo para a sua fabricacao
PT1066049E (pt) Composicoes farmaceuticas para a libertacao prolongada de peptido e processo para a sua libertacao
BR9807845B1 (pt) pó de tántalo e processo para a sua produção.
BR9810116B1 (pt) composição de solução e processo para sua preparação.
PT750907E (pt) Formulacoes de vacinas estaveis para administracao parenterica metodo para a sua utilizacao e processo para a sua preparacao
BR9505051A (pt) Composto derivado de 2,4-oxazolidinodiona processo para a sua produção e composição farmacêutica
BR9605354A (pt) Composto composição farmacêutica processo para a produção do composto e uso
BR9603609A (pt) Dispersão aquosa de polímero e processo para a sua produção
BR9606396A (pt) Derivados de camptotecin substituídos e processo para sua preparação
PT1038899E (pt) PROMOTOR DE ADESAO PARA REFORCOS TêXTEIS INTERNOS PROCESSO PARA A SUA PRODUCAO E A SUA UTILIZACAO
PT900253E (pt) Composicoes de betume e um processo para a sua preparacao
BR9408354A (pt) Composição de limpeza sólida homogénea altamente alcalina e processo para sua produção
BR9400130A (pt) Articulação esférica e processo de trabalho para sua produção
PT977736E (pt) Processo para a producao de maleato de flupirtina puro e da sua modificacao a
PT1015433E (pt) 1,2,3,4,5,6-hexa-hidro-2,6-metano-3-benzazocin-10-ois substituidos processo para a sua producao e sua utilizacao como medicamentos
BR9600289A (pt) Material de sinterização e processo para a sua preparação
BR9612457A (pt) Processo para a fabricação de felodipina
PT973769E (pt) Processo para a preparacao de eprosartan
BR9804873A (pt) Processo para a produ-Æo de ironas
BR9600732A (pt) Processo para proporcionar a estabilidade de pó de polímero aperfeiçoada
PT970073E (pt) Processo para a preparacao de eprosartan